Orchid Pharma reports strong FY25 results, announces AGM

Orchid Pharma Limited announced its 32nd annual general meeting (AGM) will be held on Saturday, September 20, 2025, at 11:30 A.M. (IST) via video conferencing. The annual report for FY 2024-25 has been made available to shareholders.

The FY 2024-25 annual report highlights significant growth, with standalone operating revenue reaching ₹921.93 crores, up from ₹819.37 crores in FY 2023-24. Profit after tax was ₹106.48 crores, compared to ₹94.75 crores in the previous year. Diluted earnings per share (EPS) increased to ₹20.99 from ₹19.59. Strategically, Orchid Pharma acquired global rights to Enmetazobactam and progressed with a ₹600 crore investment in a 7-ACA manufacturing facility in Jammu, alongside a ₹150 crore investment in an injectables facility.

The company also reported compliance with SEBI listing regulations and other statutory provisions. Key managerial appointments and re-appointments were noted, and the company emphasized its commitment to corporate governance and sustainability.